The End­points 11: They've got mad mon­ey and huge am­bi­tions. It's time to go big or go home

These days, se­lect­ing a group of pri­vate biotechs for the End­points 11 spot­light be­gins with a sprint to get ahead of IPOs and the M&A teams at Big Phar­ma. I’ve had a cou­ple of face­plants ear­li­er this year, watch­ing some of the biotechs on my short list choose a quick leap on­to Nas­daq or in­to the arms of a buy­er.

Vi­vid­ion, you would have been a great pick for the End­points 11. I’m sor­ry I missed you.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters